Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 11/20 | 0.44 |
| ▸ | THRA | P10827 | 10/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | PCNA | P12004 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3131477 | 0.92 | THRB (0.48) | THRBTHRAALDH1A1LMNAMAPT | |
| SCHEMBL14629174 | 0.89 | THRA (0.36) | THRBTHRAALDH1A1LMNAMAPT | |
| SCHEMBL14392002 | 0.86 | HDAC8 (0.40) | THRBTHRAALDH1A1LMNAMAPT | |
| SCHEMBL14386131 | 0.85 | THRA (0.42) | THRBTHRAALDH1A1LMNAMAPT | |
| SCHEMBL5077533 | 0.82 | THRB (0.43) | THRBTHRAMAPTPCNA | |
| SCHEMBL5073534 | 0.80 | THRA (0.60) | THRBTHRAPCNA | |
| SCHEMBL3908141 | 0.80 | THRA (0.49) | THRBTHRAALDH1A1LMNAMAPT | |
| SCHEMBL8580621 | 0.80 | SKP2 (0.41) | THRBTHRAALDH1A1MAPTHTT | |
| SCHEMBL8580942 | 0.79 | THRA (0.41) | THRBTHRAALDH1A1MAPT | |
| SCHEMBL3133337 | 0.78 | SMN1; SMN2 (0.43) | THRBTHRAALDH1A1KMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004271-A1 | HETEROCYCLIC COMPOUNDS AS AGANIST FOR THE THYROID RECEPTOR | KARO BIO AB (SE) | 2010-01-07 | — | — | US | disclosed |
| US-20100004271-A1 | HETEROCYCLIC COMPOUNDS AS AGANIST FOR THE THYROID RECEPTOR | KARO BIO AB (SE) | 2010-01-07 | — | — | US | disclosed |
| US-20100004271-A1 | HETEROCYCLIC COMPOUNDS AS AGANIST FOR THE THYROID RECEPTOR | KARO BIO AB (SE) | 2010-01-07 | — | — | US | disclosed |
| US-20090318514-A1 | Novel Pharmaceutical Compositions | KARO BIO AB (SE) | 2009-12-24 | — | — | US | disclosed |
| US-20090318514-A1 | Novel Pharmaceutical Compositions | KARO BIO AB (SE) | 2009-12-24 | — | — | US | disclosed |
| US-20090318514-A1 | Novel Pharmaceutical Compositions | KARO BIO AB (SE) | 2009-12-24 | — | — | US | disclosed |
| EP-2024336-A1 | NOVEL PHARMACEUTICAL COMPOSITIONS | KARO BIO AB (SE) | 2009-02-18 | — | — | EP | disclosed |
| EP-1899309-A1 | HETEROCYCLIC COMPOUNDS AS AGONISTS FOR THE THYROID RECEPTOR | KARO BIO AB (SE) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007128492-A1 | NOVEL PHARMACEUTICAL COMPOSITIONS | KARO BIO AB (SE) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007003419-A1 | HETEROCYCLIC COMPOUNDS AS AGONISTS FOR THE THYROID RECEPTOR | KARO BIO AB (SE) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004271-A1 | HETEROCYCLIC COMPOUNDS AS AGANIST FOR THE THYROID RECEPTOR | TSHR, GHSR, TRHR | THRB 6/4885THRA 4/4885ALDH1A1 1081/4885 |
| US-20090318514-A1 | Novel Pharmaceutical Compositions | TSHR, TRHR, THRA | THRB 5/4885THRA 3/4885ALDH1A1 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.